Halozyme Therapeutics Inc
NASDAQ:HALO
Halozyme Therapeutics Inc
NASDAQ:HALO
Price:
45.395 USD
0.95%
Market Closed
Updated:
May 21, 2024
P/E
Price to Earnings
Price to Earnings
18.1
Current
19.9
Median
26.1
Industry
Lower
than median
Lower
than industry value
Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.
P/E
=18.1
Market Cap
/
5.8B
Net Income
318.8m
All Countries
| Market Cap | P/E | ||||
|---|---|---|---|---|---|
| US |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
5.8B USD | 18.1 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
287.7B USD | 48.4 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
168.6B USD | 44.8 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
113.7B USD | 28.3 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
109.5B USD | 28.4 | |
| AU |
|
CSL Ltd
ASX:CSL
|
134.1B AUD | 36.2 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
83.8B USD | 173.2 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
54.4B USD | -9.1 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | -57.5 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
33B USD | 28.3 | |
| KR |
|
Celltrion Inc
KRX:068270
|
38.6T KRW | 72 |
P/E Forward Multiples
Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
P/E
12.1
2-Years Forward
P/E
9.8
3-Years Forward
P/E
7.4
You don't have any saved screeners yet
